These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 20719224)

  • 1. Quality assessment for human papillomavirus testing.
    Tabrizi SN
    Sex Health; 2010 Sep; 7(3):335-7. PubMed ID: 20719224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
    Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
    Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A peer comparison program for the quality assurance of human papillomavirus DNA detection using the Digene Hybrid Capture II/SurePath method shows excellent analytic interlaboratory correlation.
    Kuebler DL; Illingworth A; Blenc AM; Wilbur DC
    Cancer; 2007 Oct; 111(5):339-43. PubMed ID: 17879373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus testing for primary screening of cervical cancer precursors.
    Ratnam S; Franco EL; Ferenczy A
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):945-51. PubMed ID: 11008913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV testing for cervical cancer screening in Croatia.
    Grce M; Grahovac B; Rukavina T; Vrdoljak-Mozetic D; Glavas-Obrovac L; Kaliterna V; Zele-Starcević L
    Coll Antropol; 2007 Apr; 31 Suppl 2():67-71. PubMed ID: 17598507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HPV test for quality control of gynecologic cytological tests].
    Wilander E; Wikström I
    Lakartidningen; 2008 Nov 26-Dec 9; 105(48-49):3560, 3564. PubMed ID: 19133586
    [No Abstract]   [Full Text] [Related]  

  • 7. Australian women's needs and preferences for information about human papillomavirus in cervical screening.
    McCaffery K; Irwig L
    J Med Screen; 2005; 12(3):134-41. PubMed ID: 16156944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periodic health examination, 1995 update: 1. Screening for human papillomavirus infection in asymptomatic women. Canadian Task Force on the Periodic Health Examination.
    Johnson K
    CMAJ; 1995 Feb; 152(4):483-93. PubMed ID: 7859196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?
    Wright TC
    Clin Obstet Gynecol; 2007 Jun; 50(2):313-23. PubMed ID: 17513921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor.
    Zuna RE; Moore W; Dunn ST
    Mod Pathol; 2001 Mar; 14(3):147-51. PubMed ID: 11266518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV: from the cervical smear to the research bench to the court room.
    Atkins K
    Clin Leadersh Manag Rev; 2003; 17(6):341-5. PubMed ID: 14692078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cervical cancer screening: restoration or reconstruction?].
    Riethmuller D
    Gynecol Obstet Fertil; 2009; 37(7-8):671-9. PubMed ID: 19577501
    [No Abstract]   [Full Text] [Related]  

  • 13. Cervical cancer screening in the early post vaccine era.
    Waxman AG
    Obstet Gynecol Clin North Am; 2008 Dec; 35(4):537-48; vii. PubMed ID: 19061815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV testing in liquid specimens.
    Geyer SJ
    Acta Cytol; 2006; 50(5):599-600. PubMed ID: 17017457
    [No Abstract]   [Full Text] [Related]  

  • 15. Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing.
    Cuschieri K; Schuurman R; Coughlan S
    Cytopathology; 2019 May; 30(3):273-280. PubMed ID: 30657615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality control in cytopathology applied to screening for cervical carcinoma.
    Marsan C
    Pol J Pathol; 1995; 46(4):245-8. PubMed ID: 8713292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of screening for cancerous and precancerous lesions of the cervix.
    Méréa E; Le Galès C; Cochand-Priollet B; Cartier I; de Crémoux P; Vacher-Lavenu MC; Vielh P; Coste J
    Diagn Cytopathol; 2002 Oct; 27(4):251-7. PubMed ID: 12357505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women.
    Pitts MK; Heywood W; Ryall R; Smith AM; Shelley JM; Richters J; Simpson JM
    Sex Health; 2010 Sep; 7(3):299-303. PubMed ID: 20719218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma.
    Lie AK; Kristensen G
    Expert Rev Mol Diagn; 2008 Jul; 8(4):405-15. PubMed ID: 18598223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".
    Sawaya GF
    Arch Intern Med; 2010 Jun; 170(11):985-6. PubMed ID: 20548012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.